Trius unveils safety benefits for Zyvox rival tedizolid
This article was originally published in Scrip
Executive Summary
While negotiations with partners to commercialise the antibiotic tedizolid phosphate in Europe are ongoing, Trius Therapeutics is once again on the road presenting data from early-stage studies and its first Phase III clinical trial for the drug in the treatment of acute bacterial skin and skin structure infections (ABSSSI), including potential safety improvements over its main competitor, Pfizer's Zyvox (linezolid).